Metabolic and bariatric surgery has been studied for decades as a treatment option for Type 2 diabetes in people who also have obesity. The 2022 ASMBS/IFSO guidelines recognize metabolic surgery as an evidence-based option for selected patients with Type 2 diabetes and BMI ≥ 30. This article explains what "improvement" and "remission" mean in the published literature — and what they do not mean.
What does "diabetes remission" mean?
Diabetes remission is typically defined as achieving normal glucose levels (HbA1c < 6.5%) without diabetes medications for a sustained period. The American Diabetes Association distinguishes between partial remission, complete remission, and prolonged remission. Remission is not the same as a cure — diabetes can return, especially with weight regain.
What the evidence shows
- Randomized trials such as STAMPEDE and Diabetes Surgery Study show greater glycemic improvement with metabolic surgery than with medical therapy alone at 1, 3, and 5 years in selected patients.
- Outcomes vary by procedure, baseline A1c, diabetes duration, insulin use, and beta-cell reserve.
- Long-term follow-up shows some patients relapse, which is why ongoing medical care is essential after surgery.
Who tends to do best?
Published predictors of better glycemic outcomes include shorter diabetes duration, lower baseline A1c, absence of insulin use, and preserved beta-cell function. None of these guarantees a specific outcome for an individual patient.
What MagnaMetabolic does not claim
MagnaMetabolic does not promise diabetes cure, guaranteed remission, or specific weight-loss results. The MagDI™ System received FDA De Novo authorization for the creation of side-to-side duodeno-ileal anastomoses; FDA documentation states that the effects of the device on weight loss were not studied.
Next step
A personalized evaluation by qualified healthcare professionals is required to determine whether metabolic surgery is an appropriate option for you.